Effectiveness of angiotensin receptor inhibitors and non-lysine in functional mitral regurgitation

Objective: sacubitrile/valsartan is superior to valsartan in modifying functional mitral regurgitation (MR) for the better thanks to the double inhibition of the renin-angiotensin and neprilysin system.
Material and methods. This double-blind study randomly assigned sacubitrile/valsartan or valsartan in addition to standard drug therapy for heart failure among 90 patients with heart failure with chronic functional MR (secondary to left ventricular (LV) dysfunction). The primary endpoint was a change in the effective area of the regurgitation hole during the 12-month follow-up. Secondary endpoints included changes in the volume of regurgitation, the final systolic volume of the left ventricle, the final diastolic volume of the left ventricle, and the area of incomplete closure of the mitral valves.
Results. The decrease in the effective area of the regurgitation hole was significantly more pronounced in the sacubitrile/valsartan group than in the valsartan group (–0.048 ± 0.095 vs –0.012 ± 0.105 cm2; p = 0.032) in the treatment efficacy analysis, which included 90 patients (100%). The regurgitation volume also significantly decreased in the sacubitrile/valsartan group compared to the valsartan group (mean difference –7.3 ml; 95% CI 12.6–1.9; p = 0.009). There were no significant differences between the groups regarding changes in the area of incomplete closure of the mitral valves and LV volumes, with the exception of the index of the final LV diastolic volume (р = 0.044). There were no significant differences in the change in blood pressure between the two treatment groups.
Conclusion. Among patients with secondary functional MR, sakubitril/valsartan reduced MR more than valsartan. Thus, angiotensin receptor inhibitors and neprilysin can be considered for optimal drug treatment of patients with heart failure and functional MR.

1. Pirard L.A., Carabello B.A.. Ischaemic mitral regurgitation: pathophysiology,outcomes and the conundrum of treatment. Eur. Heart J. 2010;31:2996–3005. doi: 10.1093/eurheartj/ehq411

2. Rossi A. Dini F.L., Faggiano P. et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and nonischaemic dilated cardiomyopathy. Heart. 2011;97:1675–80. doi: 10.1136/hrt.2011.225789

3. Mareev V.Yu., Ageev F.T., Arutyunov G.P. et al. Clinical recommendations OSSN — RKO — RNMOT. Heart failure: chronic (CHF) and acute decompensated (ODSN). Diagnosis, prevention and treatment. Cardiologiia. 2018;58(S6). DOI: 10.18087/cardio.2475 (in Russian)

4. Nishimura R.A., Otto C.M., Bonow R.O. et al.; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521–e643. doi: 10.1161/CIR.0000000000000031

5. Mareev Yu.V., Mareev V.Yu. Characterization and treatment of patients with heart failure hospitalized in a hospital. Cardiologiia. 2017;57(S4):20–30. DOI:10.18087/cardio.2433] (in Russian)

6. Belenkov Yu.N., Mareev V.Yu., Ageev F.T. Chronic heart failure. Selected lectures on cardiology. 2006. ISBN: 5-9704-0119-6 (in Russian)

7. Asgar A.W., Mack M.J., Stone G.W. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J. Am. Coll. Cardiol. 2015;65:1231–48. doi: 10.1016/j.jacc.2015.02.009

8. Agricola E., Ielasi A. Oppizzi M. et al. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur. J. Heart Fail. 2009;11:581–7. doi: 10.1093/eurjhf/hfp051

9. McMurray J.J., Packer M., Desai A.S. et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077

10. Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509

11. Hubers S.A., Brown N.J. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115–24. doi: 10.1161/CIRCULATIONAHA.115.018622

12. Sacks C.A., Jarcho J.A., Curfman G.D. Paradigm shifts in heart-failure therapy–a timeline. N. Engl. J. Med. 2014;371:989–91. doi: 10.1056/NEJMp1410241

13. Ruilope L.M., Dukat A., Bцhm M. et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. doi: 10.1016/S0140-6736(09)61966-8

14. Solomon S.D., Zile M., Pieske B. et al. Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95. doi: 10.1016/S0140-6736(12)61227-6

15. Milani R.V., Drazner M.H., Lavie C.J. et al. Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am. J. Cardiol. 2011;108:992–6. doi: 10.1016/j.amjcard.2011.05.038

16. Grayburn P.A., Weissman N.J., Zamorano J.L. Quantitation of mitral regurgitation. Circulation. 2012;126:2005–17. doi: 10.1161/CIRCULATIONAHA.112.121590

17. Kang D.H., Sun B.J., Kim D.H. et al. Percutaneous versus surgical revascularization in patients with ischemic mitral regurgitation. Circulation. 2011;124(11 Suppl):S156–S162. doi: 10.1161/CIRCULATIONAHA.110.011254

18. Nishimura R.A., Vahanian A., Eleid M.F. et al. Mitral valve disease– current management and future challenges. Lancet. 2016;387:1324– 34. doi: 10.1016/S0140-6736(16)00558-4

19. Greenberg B., Quinones M.A., Koilpillai C. et al. Effects of longterm enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573–81. doi: 10.1161/01.CIR.91.10.2573

20. Chaput M., Handschumacher M.D., Tournoux F. et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation. 2008;118:845–52. doi: 10.1161/CIRCULATIONAHA.107.749440

21. Michler R.E., Rouleau J.L., Al-Khalidi H.R. et al. STICH Trial Investigators. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J. Thorac. Cardiovasc. Surg. 2013;146:1139–45.e6. doi: 10.1016/j.jtcvs.2012.09.007